文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

应用筛查法利用常规监测数据估计COVID-19疫苗有效性:德国在COVID-19大流行期间的经验,2021年7月至2023年3月

Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany's experience during the COVID-19 pandemic, July 2021 to March 2023.
PubMed 文献 · Euro Surveill · 2024-01-01

本文介绍德国在通知数据、实验室检测数据和疫苗覆盖数据因严格数据保护要求无法链接的情况下,于2021年7月至2023年3月持续使用筛查法估计COVID-19疫苗有效性,期间 Delta 和 Omicron 变异株流行,实时产出不同年龄组和临床结局的疫苗有效性估计,并总结该方法的优势、局限及实践指导。

要点

  • 筛查法可利用无法链接的常规疾病监测和疫苗覆盖数据快速估计疫苗有效性。
  • 德国于2021年7月至2023年3月持续应用筛查法评估COVID-19疫苗有效性。
  • 实践指导涉及病例定义严格性、检测行为和数据分层等需在分析和解释结果时仔细考虑的问题。

核心结论

  • 德国使用筛查法估计COVID-19疫苗有效性的整体经验是积极的,该方法可实时产出不同年龄组和临床结局的疫苗有效性估计。

研究设计与样本

  • 本文描述德国在2021年7月至2023年3月期间使用筛查法,基于常规疾病监测和疫苗覆盖数据估计COVID-19疫苗有效性的经验。

主要发现

  • 在Delta和Omicron变异株流行期间,筛查法实时产出了不同年龄组和临床结局的COVID-19疫苗有效性估计。

临床怎么用

  • 作者提供实践指导,指出病例定义严格性、检测行为和数据分层等问题需在数据分析与结果解释时仔细考虑。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The screening method represents a simple, quick, and practical tool for estimating vaccine effectiveness (VE) using routine disease surveillance and vaccine coverage data, even if these data cannot be linked. In Germany, where notification data, laboratory testing data, and vaccine coverage data cannot be linked due to strict data protection requirements, the screening method was used to assess COVID-19 VE continuously between July 2021 and March 2023. During this period, when Delta and Omicron variants circulated, VE estimates were produced in real-time for different age groups and clinical outcomes. Here we describe the country's overall positive experience using the screening method, including its strengths and limitations, and provide practical guidance regarding a few issues, such as case definition stringency, testing behaviour, and data stratification, that require careful consideration during data analysis and the interpretation of the results.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Perumal N, Schönfeld V, Wichmann O, et al. Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany's experience during the COVID-19 pandemic, July 2021 to March 2023. Euro Surveill. 2024. PMID: 38390650. doi:10.2807/1560-7917.ES.2023.29.8.2300329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。